[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma].

Authors :: Ohtake Y
Sudo K
Kojima Y
Seo T
Okuma H
Nishikawa T
Uno M
Uehara T
Ishikawa M
Tanioka M
Noguchi E
Shimomura A
Yonemori K
Kato T
Fujiwara Y
Tamura K
Source :: Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2019 Oct; Vol. 46 (10), pp. 1525-1529.
Publication Year :: 2019
Abstract: Aim: This study aimed to retrospectively evaluate the efficacy and safety of ifosfamide plus paclitaxel(IT)in Japanese patients with recurrent or metastatic uterine carcinosarcoma.<br />Methods: This study included 15 patients who received IT(ifosfamide [1.6 g/m / 2 on days 1-3]and paclitaxel[135mg/m2 on day 1]every 3 weeks)for recurrent or metastatic uterine carcinosarcoma.<br />Results: The overall response rate was 38.4%, and the disease control rate was 92.3%. The median progression- free survival was 7.0 months, and the median overall survival was 9.0 months after initiation of IT therapy. The most common hematological adverse event was Grade 1-2 neutropenia. Peripheral neuropathy of Grade 1 or 2 was observed in 33.3% of cases. There was no treatment-related death.<br />Conclusion: IT therapy showed good efficacy and tolerability in Japanese patients with recurrent or metastatic uterine carcinosarcoma.